Search Bar & Filters
Found 13 Actively Recruiting clinical trials
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC, a type of kidney cancer. This study compares a standard targeted therapy called belzutifan with a combination of belzutifan and another targeted therapy, zanzalintinib. The goal is to find out if adding zanzalintinib helps people with advanced RCC live longer and without their cancer worsening compared to belzutifan alone. Participants will be randomly assigned to one of two groups. One group will take 120 mg of belzutifan orally plus 60 mg of zanzalintinib once daily for about 24 months. The other group will take 120 mg of belzutifan plus a placebo matching zanzalintinib once daily for the same period. Both treatments are given as tablets taken by mouth. During the study, participants will have regular evaluations to monitor their cancers status, side effects, and quality of life. Researchers will use specific measures such as progression-free survival PFS and overall survival OS over up to 50 months. Other assessments include tumor response, duration of response, adverse events, and changes in health questionnaires related to physical function and symptoms. Safety and treatment effects will be carefully tracked throughout the study.
Actively Recruiting
Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.
Actively Recruiting
Researchers are evaluating new treatment approaches for advanced ovarian cancer in people whose tumors are non-HRD positive. This study aims to find out if adding sacituzumab tirumotecan sac-TMT, a targeted therapy, as maintenance treatmentwith or without bevacizumabhelps patients live longer without their cancer worsening compared to standard care. This is a phase 3 randomized study involving participants who have completed surgery and first-line platinum-based chemotherapy. Participants receive sac-TMT intravenously on days 1, 15, and 29 of every 6-week cycle until their disease worsens or they experience prohibitive side effects. Some may also receive bevacizumab intravenously on days 1 and 22 every 6 weeks for up to 22 cycles, depending on the investigators choice. The comparison group receives either bevacizumab alone on the same schedule or is observed closely without maintenance treatment. During the study, participants will have regular evaluations to monitor their cancer status and quality of life. Researchers will measure progression-free survival for up to about 49 months and assess overall survival, adverse events, treatment discontinuation, and changes in quality of life scores for up to 78 months. Participants health will be followed long-term to understand treatment effects and safety over time.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of rilvegostomig combined with fluoropyrimidine and trastuzumab deruxtecan T-DXd compared to trastuzumab, chemotherapy, and pembrolizumab in participants with HER2-positive locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma whose tumors express PD-L1 combined positive score CPS of 1 or higher. This Phase 3, randomized, open-label study also includes a separate group receiving rilvegostomig with trastuzumab and chemotherapy to understand the contribution of each treatment component. The study is being conducted globally across many sites in about 25 countries. Participants are assigned to one of three treatment groups Arm A receives rilvegostomig, fluoropyrimidine capecitabine or 5-fluorouracil, and trastuzumab deruxtecan Arm B receives pembrolizumab, trastuzumab, and chemotherapy 5-fluorouracil plus cisplatin or capecitabine plus oxaliplatin Arm C receives rilvegostomig, trastuzumab, and chemotherapy. Treatments are administered mainly through intravenous infusions every three weeks, with capecitabine taken orally twice daily. The study aims to assess the role of each treatment combination over time. During the study, participants will undergo regular assessments including tumor measurements, safety checks for adverse events, and blood tests to monitor drug levels and immune responses. Researchers will track progression-free survival and overall survival for up to six years, along with response rates and treatment side effects. The study includes ongoing monitoring for eating difficulties and side-effect impact. Participants will be followed closely throughout treatment and for years afterward to evaluate long-term outcomes and safety.
Actively Recruiting
Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of sacituzumab tirumotecan combined with bevacizumab, as well as sacituzumab tirumotecan alone, compared to standard care in women with platinum-sensitive recurrent ovarian cancer. The study aims to understand if these treatments help participants live longer without their cancer worsening. This is a Phase 3, randomized, open-label trial sponsored by Merck Sharp & Dohme LLC. Participants are assigned to one of three groups. One group receives sacituzumab tirumotecan every two weeks plus bevacizumab every three weeks for six weeks. Another group receives sacituzumab tirumotecan every two weeks for up to about two years, possibly with bevacizumab at the doctors choice. The third group receives standard care, with optional bevacizumab per the physicians decision, until disease progression or discontinuation. Throughout the study, participants undergo regular intravenous infusions and are monitored for adverse events, treatment tolerance, and cancer progression. Researchers also assess quality of life using questionnaires. Safety is closely observed up to six weeks for initial side effects and for approximately four years to evaluate progression-free survival. Overall survival and long-term safety are followed for up to six years, with ongoing assessments of physical and role functioning and abdominal symptoms related to ovarian cancer.
Actively Recruiting
This research aims to evaluate the effectiveness of AZD5335 compared to standard treatments in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer. The study focuses on whether AZD5335 improves progression-free survival PFS among participants with either high or low levels of folate receptor alpha FR. Approximately 1100 adult women will be enrolled and divided into two groups based on their FR levels. Participants will be randomized within each group to receive either AZD5335 or the relevant standard treatment. Those with high FR levels will receive AZD5335 or mirvetuximab soravtansine, while those with low FR levels will receive AZD5335 or a chemotherapy agent chosen by the investigator, including paclitaxel, pegylated liposomal doxorubicin, or topotecan. Treatments are given intravenously, and participants will continue treatment until disease progression or other reasons for stopping. During the study, participants will undergo regular tumor assessments to monitor disease status. Researchers will follow all participants over time to evaluate overall survival. Safety and efficacy data will be reviewed periodically by an independent committee. The primary outcome is progression-free survival, measured for up to about five years. The study completion is expected by late 2029.
Actively Recruiting
Researchers are evaluating the clinical effectiveness of different Dialectical Behavior Therapy DBT approaches for individuals with Borderline Personality Disorder BPD within public mental health services in Chile. The study compares a 12-week DBT skills training group with a 24-week quasi-standard DBT program and treatment as usual. This trial aims to understand whether the shorter DBT skills training can be as effective as the longer standard treatment in reducing suicidal and self-harming behaviors. The study involves three groups an enhanced 13-week DBT skills training program including orientation, weekly skills groups, phone check-ins, emergency coaching, and team meetings a 24-week standard DBT program with preparatory individual sessions, weekly skills groups, individual therapy, phone coaching during office hours, and consultation meetings and treatment as usual consisting of monthly or biweekly individual psychotherapy sessions at community mental health centers. These interventions are delivered in routine public healthcare settings and aim to assess different treatment durations and structures. Participants will be assessed using many tools to track changes in suicidal behavior, psychopathology, borderline symptoms, emotion regulation, dissociation, depression, trauma, functioning, personality traits, substance use, disability, quality of life, social isolation, satisfaction, costs, and stress. Assessments occur at baseline, weekly during intervention, and at 3 and 6 months post-start. The main outcome measures focus on suicidal severity ratings at baseline, 3 months, and 6 months. The total study duration is about 6 months per participant, with ongoing monitoring and evaluation throughout.
Actively Recruiting
Researchers are evaluating the use of Zanidatamab combined with standard chemotherapy drugs Cisplatin and Gemcitabine, with or without an additional immune therapy drug chosen by the doctor, for adults with HER2-positive biliary tract cancer. This study aims to assess the effectiveness and safety of adding Zanidatamab to the current standard treatment for this advanced cancer type. Participants will be randomly assigned to receive either Zanidatamab plus Cisplatin and Gemcitabine with or without a PD-1L1 inhibitor either Durvalumab or Pembrolizumab or the standard treatment of Cisplatin and Gemcitabine with or without the same immune therapy drugs. All medications are given through intravenous infusions. The study treatment continues under medical supervision and may vary according to local drug approvals. During the trial, participants will have regular assessments including tumor evaluations to measure progression-free survival and overall survival, along with monitoring treatment response and side effects. Patient-reported outcomes on physical functioning and symptom severity will also be collected. The study may last up to several years, with continuous safety monitoring and follow-up visits to evaluate long-term effects and treatment impact.
Actively Recruiting
Gallbladder cancer GBC is a serious disease often linked to gallstones, especially in women. This research focuses on improving the early detection and prevention of GBC by studying various factors including geography, environment, lifestyle, ethnicity, gender, and molecular markers. The goal is to better estimate the risk of developing GBC and to help guide prevention and treatment decisions, supported by a European-Latin American research collaboration. Participants include those with gallbladder cancer or dysplasia, both before and after starting treatment, as well as individuals with gallstones scheduled for gallbladder removal surgery. The study involves collecting epidemiological, clinical, and dietary data along with biological samples such as blood, saliva, urine, bile, feces, and gallbladder tissue to identify and study new biomarkers and risk factors for GBC. Throughout the study, researchers will use this information to build a biorepository and develop a risk score that integrates multiple factors linked to GBC. They will monitor participants for the development of gallbladder cancer or dysplasia through standard hospital protocols. The study aims to support future personalized prevention strategies and targeted therapies while training new researchers in precision medicine for GBC. Participation involves data and sample collection with ongoing follow-up to assess disease development.
1-10 of 13
1